A new research gave a breakthrough with a suggestion that drugs that treat bone loss known to be Bisphosphonates may lower the risk of endometrial cancer.
Women taking the drugs had about half the risk of endometrial cancer as compared to women who do not take the drugs was found in the study. One of the most common types of cancer found in women known as endometrial cancer affects the lining of the uterus.
Actonel, Boniva and Fosamax are the brand names of medications which include Bisphosphonates for the treatment of endometrial cancer.
The medical records of women who took bisphosphonates that contain nitrogen, which is though to boost anti-cancer abilities was examined by the researchers. Overall 30,000 women were studied by the researchers. Moreover, they accounted for factors such as age, race and smoking status while assessing risk.
Journal Cancer published the study in the issue of December 22.
“Other studies have shown that bisphosphonates may reduce the risk of certain cancers, but we are the first to show that the risk for endometrial cancer may also be reduced,” Sharon Hensley Alford, a public health researcher from the Henry Ford Health System in Detroit, said in a statement from the journal.
“This study suggests that women who need bone-strengthening medications and who have increased risk for endometrial cancer may want to choose the nitrogen form of bisphosphonates because this form may reduce the risk of endometrial cancer,” she said.
A connection between the bone-preserving medications and reduced risk of endometrial cancer was found in the study. However, it did not prove the cause and effect of it.